Peter S. Kim

CIK: 0001181180

Transaction Breakdown

Open Market Buys (P)2 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TRDA

Entrada Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

TRDA
Entrada Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-
TRDA
Entrada Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-
TRDA
Entrada Therapeutics, Inc.
May 14, 2024
Purchase(P)
Direct
25K shares at avg. $14.59$365K
TRDA
Entrada Therapeutics, Inc.
May 13, 2024
Purchase(P)
Direct
25K shares at avg. $14.68$367K

		Type	Shares	Price		Ownership
Jun 10, 2026	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct
Jun 11, 2025	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct
May 14, 2024	TRDA Entrada Therapeutics, Inc.	Purchase(P)	25,000	$14.59	$364,673	Direct
May 13, 2024	TRDA Entrada Therapeutics, Inc.	Purchase(P)	25,000	$14.68	$367,010	Direct

1-4 of 4 transactions

About KIM PETER S

KIM PETER S (SEC CIK 0001181180) files insider reports with the SEC as Director of Entrada Therapeutics, Inc. (TRDA).

Signal8 holds 3 ownership filings by KIM PETER S, all Form 4s, filed between Jun 12, 2025 and Jun 12, 2026. Those filings report 4 transactions, from May 13, 2024 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on KIM PETER S's filings is in BOSTON, MA.

Recent filings by KIM PETER S

Jun 10, 2026: Grant or award of TRDA derivative securities (Form 4, code A).
Jun 11, 2025: Grant or award of TRDA derivative securities (Form 4, code A).
May 14, 2024: Open-market purchase of TRDA shares (Form 4, code P).
May 13, 2024: Open-market purchase of TRDA shares (Form 4, code P).

Other insiders filing for Entrada Therapeutics, Inc. (TRDA)

MPM BIOVENTURES 2018, L.P., 10% Owner
MPM BioVentures 2014, L.P., 10% Owner
Doshi Dipal, CEO
Dowden Nathan J, President & COO
Sethuraman Natarajan, President, Research & Develop.
WENTWORTH KORY JAMES, Chief Financial Officer

How to read Form 4 transaction codes